IL6R and neoplasm: We tested the in vitro cell killing activity of primary human T cells and CD126-targeted CAR-T cells after co-culture with 15 different tumor cell lines, including MM (RPMI-8226, U266B1, MM1.S, KMS-12-PE), AML (HL-60), lymphoma (SU-DHL-1, KARPAS 299), T cell leukemia (Jurkat, MOLT-4), CML (K562), prostate cancer (DU145, LNCaP), malignant melanoma (624-mel), lung adenocarcinoma (A549), hepatocellular carcinoma (HepG2), and glioblastoma (U-251 MG).